The discriminative stimulus effects of baclofen and gamma hydroxybutyrate in C57BL/6J mice. 2022

Jenny L Wilkerson, and Takato Hiranita, and Wouter Koek, and Lance R McMahon
Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, Florida.

Baclofen and γ-hydroxybutyrate (GHB) exert γ-aminobutyric acid (GABA)B receptor agonism and have therapeutic utility but possess different pharmacological activities. We examined whether separate groups of mice could be trained to discriminate either baclofen or GHB, and the contribution of GABAB receptors to discriminative stimulus effects. Male C57BL/6J mice were trained to discriminate either baclofen (3.2 mg/kg, intraperitoneal) or GHB (178 mg/kg, intraperitoneal) from saline under a fixed-ratio 10 schedule. The GABAB antagonist 3-aminopropyl(diethoxymethyl)phosphinic acid (CGP 35348) was used to pharmacologically assess GABAB receptor involvement. The selectivity of the resulting discriminations was assessed with the opioid agonist morphine and the benzodiazepine midazolam. In baclofen-trained mice, both baclofen and GHB were readily discriminated. Baclofen produced a maximum of 86% baclofen-appropriate responding. CGP 35348 (320 mg/kg, i.p.) produced a 4.7-fold rightward shift in the dose-effect function. GHB produced a maximum of 85.8% baclofen-appropriate responding. In GHB-trained mice, both GHB and baclofen were readily discriminated. In GHB-trained mice, GHB produced a maximum of 85.3% drug-appropriate responding; CGP 35348 (320 mg/kg, i.p.) produced a 1.8-fold rightward shift in the GHB discrimination dose-effect function. Baclofen produced up to 70.0% GHB-appropriate responding. CGP 35348 (320 mg/kg, i.p.) significantly antagonized baclofen discrimination and baclofen produced up to 37% GHB-appropriate responding up to doses that disrupted operant responding. Morphine did not produce substitution for either baclofen or GHB. Midazolam produced partial substitution for both. GHB and baclofen discrimination assays in mice provide a useful approach for examining different receptor types mediating the effects of these two drugs.

UI MeSH Term Description Entries
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008874 Midazolam A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH. Dormicum,Midazolam Hydrochloride,Midazolam Maleate,Ro 21-3981,Versed,Hydrochloride, Midazolam,Maleate, Midazolam,Ro 21 3981,Ro 213981
D009022 Morphine Derivatives Analogs or derivatives of morphine. Morphines
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001418 Baclofen A GAMMA-AMINOBUTYRIC ACID derivative that is a specific agonist of GABA-B RECEPTORS. It is used in the treatment of MUSCLE SPASTICITY, especially that due to SPINAL CORD INJURIES. Its therapeutic effects result from actions at spinal and supraspinal sites, generally the reduction of excitatory transmission. Baclophen,Chlorophenyl GABA,Apo-Baclofen,Atrofen,Ba-34,647,Ba-34647,Baclofen AWD,Baclofène-Irex,Baclospas,CIBA-34,647-BA,Clofen,Gen-Baclofen,Genpharm,Lebic,Lioresal,Liorésal,Nu-Baclo,PCP-GABA,PMS-Baclofen,beta-(Aminomethyl)-4-chlorobenzenepropanoic Acid,beta-(p-Chlorophenyl)-gamma-aminobutyric Acid,AWD, Baclofen,Apo Baclofen,ApoBaclofen,Ba34,647,Ba34647,Baclofène Irex,BaclofèneIrex,CIBA34,647BA,GABA, Chlorophenyl,Gen Baclofen,GenBaclofen,Nu Baclo,NuBaclo,PMS Baclofen,PMSBaclofen
D012978 Sodium Oxybate The sodium salt of 4-hydroxybutyric acid. It is used for both induction and maintenance of ANESTHESIA. 4-Hydroxybutyrate Sodium,Oxybate Sodium,Sodium Oxybutyrate,Sodium gamma-Hydroxybutyrate,gamma-Hydroxybutyrate,Somsanit,Xyrem,4 Hydroxybutyrate Sodium,Oxybate, Sodium,Oxybutyrate, Sodium,Sodium gamma Hydroxybutyrate,gamma Hydroxybutyrate
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D018080 Receptors, GABA-B A subset of GABA RECEPTORS that signal through their interaction with HETEROTRIMERIC G-PROTEINS. Baclofen Receptors,GABA-B Receptors,Baclofen Receptor,GABA receptor rho1,GABA type B receptor, subunit 1,GABA(B)R1,GABA(B)R1 receptor,GABA(B)R1a protein,GABA(B)R1a receptor,GABA(B)R1b protein,GABA(B)R1b receptor,GABA-B Receptor,GABBR1 protein,GB1a protein,GB1b protein,GBR1B protein,Receptors, Baclofen,rho1 subunit, GABA receptor
D018755 GABA Agonists Endogenous compounds and drugs that bind to and activate GAMMA-AMINOBUTYRIC ACID receptors (RECEPTORS, GABA). gamma-Aminobutyric Acid Agonists,GABA Agonist,GABA Receptor Agonist,GABA Receptor Agonists,gamma-Aminobutyric Acid Agonist,Acid Agonist, gamma-Aminobutyric,Acid Agonists, gamma-Aminobutyric,Agonist, GABA,Agonist, GABA Receptor,Agonist, gamma-Aminobutyric Acid,Agonists, GABA,Agonists, GABA Receptor,Agonists, gamma-Aminobutyric Acid,Receptor Agonist, GABA,Receptor Agonists, GABA,gamma Aminobutyric Acid Agonist,gamma Aminobutyric Acid Agonists

Related Publications

Jenny L Wilkerson, and Takato Hiranita, and Wouter Koek, and Lance R McMahon
September 2020, Behavioural pharmacology,
Jenny L Wilkerson, and Takato Hiranita, and Wouter Koek, and Lance R McMahon
February 2011, Behavioural pharmacology,
Jenny L Wilkerson, and Takato Hiranita, and Wouter Koek, and Lance R McMahon
June 2002, Alcoholism, clinical and experimental research,
Jenny L Wilkerson, and Takato Hiranita, and Wouter Koek, and Lance R McMahon
July 2005, The Journal of pharmacology and experimental therapeutics,
Jenny L Wilkerson, and Takato Hiranita, and Wouter Koek, and Lance R McMahon
August 2009, European journal of pharmacology,
Jenny L Wilkerson, and Takato Hiranita, and Wouter Koek, and Lance R McMahon
October 2000, Neuropharmacology,
Jenny L Wilkerson, and Takato Hiranita, and Wouter Koek, and Lance R McMahon
August 2005, Alcohol (Fayetteville, N.Y.),
Jenny L Wilkerson, and Takato Hiranita, and Wouter Koek, and Lance R McMahon
June 2005, Psychopharmacology,
Jenny L Wilkerson, and Takato Hiranita, and Wouter Koek, and Lance R McMahon
April 2006, The Journal of pharmacology and experimental therapeutics,
Jenny L Wilkerson, and Takato Hiranita, and Wouter Koek, and Lance R McMahon
July 2008, Psychopharmacology,
Copied contents to your clipboard!